Brief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
13/04/2026 07:35
April 13 (Reuters) - AcuCort AB ACUC.TE: REACHES AGREEMENT WITH FDA ON INITIAL PEDIATRIC STUDY PLAN FOR ZEQMELIT PLANS TO APPLY FOR US MARKET APPROVAL FOR ZEQMELIT IN 2026 Source text: ID:nWkr3NFBvj Further company coverage: ACUC.TE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA